FDA Warning Regarding Lipokinetix Weight Loss Supplement


December 10, 2001

Warning available at: http://www.fda.gov/Food/DietarySupplements/Alerts/default.htm

LipoKinetix (Syntrax Innovations,Inc.) is a weight loss supplement that has been implicated as the cause of liver damage in six cases reported to the FDA. The product contains a combination of phenylpropanolamine, caffeine, yohimbine, diidothyronine, and sodium usniate. All cases involved healthy adults between the ages of 20 and 32 years. Hepatic injury was noted 2 weeks to 3 months after initation of LipoKinetix.

Patients should be made aware of this serious adverse effect. Patients should immediately report any nausea, weakness, fatigue, fever, abdominal pain, or jaundice that occurs while using this product. Adverse events that occur from this or any dietary supplement can be reported to FDA event reporting system Medwatch. Available at: www.fda.gov/medwatch